Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. - Wikidata - wikimedia - TriplyDB

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

http://www.wikidata.org/entity/Q43648034

about

Mechanism of action of lenalidomide in hematological malignancies Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide Thalidomide analogues as anticancer drugs Biological response modifiers in cancer Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications Current Trends of Renal Impairment in Multiple Myeloma Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Nutritional immunology: function of natural killer cells and their modulation by resveratrol for cancer prevention and treatment Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Immune Modulation in Hematologic Malignancies Lenalidomide and chronic lymphocytic leukemia Immune reconstitution in chronic lymphocytic leukemia Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy Development of Novel Immunotherapies for Multiple Myeloma The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide Thalidomide and rituximab in Waldenstrom macroglobulinemia Update on therapeutic options in Waldenström macroglobulinemia Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function Emerging drugs for chronic lymphocytic leukaemia."Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.Thalidomide for the treatment of idiopathic myelofibrosis.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Immunomodulatory drugs in myelodysplastic syndromes.Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.Targeted therapy in melanoma.

P2860

Q21198872-D13634F2-92CF-4E6E-870E-FE18AF51758D Q24605861-49E73647-3F66-4BBD-B933-21C09E4DA7C4 Q24614147-566D4339-B3FC-412D-8DA8-B885CC13240C Q24670383-56605C27-CCCC-490A-BE90-9E179BDF8F9D Q24685049-65FC8520-BD07-4068-8C79-EDECD91AEA48 Q24685895-DD3C21A9-31D8-4EA4-A105-AC663E20B1FF Q26740444-7DFBF704-DD6A-47A9-8EC9-8FBC3DAB8AAD Q26751011-F96D03AB-26CC-4A55-918A-8AC255839FC8 Q26753067-79D3A22A-3AF0-41DE-82E1-E9B592ED25D7 Q26768699-1FD92E98-7CB1-42B1-BA2E-9847FD6856A5 Q26770391-519BAED9-F74B-45F0-8775-1B93898255B0 Q26796307-C8818E90-E804-4011-BBB6-5806675A384F Q26823597-53230304-E8BA-48BE-9B3D-A2C8D4DA9F6E Q26865561-F64A16C2-9ABD-4EA8-BC36-1E0E256C9153 Q27001318-5C445EAC-B53E-427D-8D9B-C08586DA4C08 Q27008625-B837AB24-1390-45FC-B234-D5A241BC69EC Q28066890-896F9CC9-B752-43FE-8047-E7FCDDCF2614 Q28084478-089E95B2-4F35-4392-BA44-82541063180B Q28192646-6BD54419-32FA-4D65-BCCC-8E9A2C9A332B Q28291293-87F5E5C5-426A-42F0-ACA4-CA5F8348BBBC Q28304195-8C139E6B-56C7-4B5E-B1A2-FAD93FA4002D Q28383385-C795D839-AFE6-49C9-9ACB-B21ADD286A46 Q30353154-18812D62-A702-4BEA-B221-9A4535FE05C7 Q30657752-BCFC8B59-2E8B-469F-A493-C3152CD71BF1 Q33322921-BB272BC6-B8CE-4F57-B38C-0201415D290F Q33359542-A240B538-B669-4297-B80C-20AC4A775B8C Q33364235-3F4979A5-FDFB-4460-B57E-1DD508C5D469 Q33371622-93019365-A495-421C-A9FB-D76AC99D590A Q33382047-46F11A3A-D142-403C-8928-058B8D6D92FF Q33385308-C75E88D8-DEE5-47B1-BE34-730F8994CE3D Q33389026-1F1209D1-2804-4030-AE7D-CA60013BAAA8 Q33391803-3CD18BE5-1797-4838-91F4-A147DCBCD1A9 Q33398044-6727F247-73BB-4C17-9E40-6EF963568D12 Q33403183-CEB8AFF1-B62B-4F73-8B3E-9B3B003D7E34 Q33406035-3CEBE238-1911-4DB0-A4AF-DBF6BE67DE97 Q33413142-83E24DF9-BED4-4596-8476-3D4D7CADD701 Q33420263-45D58FBF-EB66-45C9-8724-078AB54E2619 Q33431621-D3F4E702-BAA3-4DA9-A43B-359889D44890 Q33440533-424478F8-C1A0-4AB0-B17C-E766A489D71E Q33573107-CB2BD3BE-EA8D-4087-A1BF-33E05A2141B3

P2860

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

http://www.wikidata.org/entity/Q43648034

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Thalidomide and immunomodulato ...... otoxicity in multiple myeloma.

@en

Thalidomide and immunomodulato ...... otoxicity in multiple myeloma.

@nl

type

label

Thalidomide and immunomodulato ...... otoxicity in multiple myeloma.

@en

Thalidomide and immunomodulato ...... otoxicity in multiple myeloma.

@nl

prefLabel

Thalidomide and immunomodulato ...... otoxicity in multiple myeloma.

@en

Thalidomide and immunomodulato ...... otoxicity in multiple myeloma.

@nl

P1433

Q43648034-CC861808-501D-4DB0-AD7C-AF9CD896355E

P1476

Q43648034-8F6E492B-FE4C-48D1-B4A6-A68E2B1BBF3D

P2093

Q43648034-07A6BA13-D084-47C6-854E-21BC46F0523A

Q43648034-09D99D1C-64C7-4967-BA55-F11DE052CAFB

Q43648034-28CF6D52-A578-4C13-883F-F98A9FBD6735

Q43648034-3097625A-AA7F-4805-86B0-0595815E3DED

Q43648034-3C828949-CAF9-4C31-A9C8-2F77B7D24617

Q43648034-4113D79A-301D-4D05-BC0E-2D18EFC80A7B

Q43648034-543946C5-5830-44FF-A460-7E134ADEAFCD

Q43648034-55345A1B-96CD-4A1F-8330-44A5E43F38DF

Q43648034-7710355C-0899-401C-947B-015C98FD0C09

Q43648034-88960F5C-6BDB-4B0B-8C94-5FF227A54ACE

P304

Q43648034-701DC91D-3A04-4319-B72D-0CD844DFABB6

P31

Q43648034-FFF0680C-1959-4838-A045-41006E05F8E8

P356

Q43648034-D1251BB1-6A39-41CB-AEF7-32231EE48293

P407

Q43648034-D527DB18-41F3-411A-B4DE-039431A2D9FC

P433

Q43648034-805B7C43-F985-412A-90AF-F529C1314D38

P478

Q43648034-594E805F-9029-4D17-B40B-08A63E71C50D

P577

Q43648034-4093C704-5F82-437E-A0BC-63B2B12BEC09

P698

Q43648034-18E4870B-BDB8-42FD-86BF-5760560D954B

P921

Q43648034-78255592-3046-4A60-BD26-4F3D387BE488

Q43648034-A56C534B-4CFC-4D08-9731-F5F7D29740CB

P356

BLOOD.V98.1.210

P1433

P1476

Thalidomide and immunomodulato ...... otoxicity in multiple myeloma.

@en

P2093

Anderson KC

http://www.w3.org/2001/XMLSchema#string

Chauhan D

http://www.w3.org/2001/XMLSchema#string

Davies FE

http://www.w3.org/2001/XMLSchema#string

Gupta D

http://www.w3.org/2001/XMLSchema#string

Hideshima T

http://www.w3.org/2001/XMLSchema#string

Lentzsch S

http://www.w3.org/2001/XMLSchema#string

Lin B

http://www.w3.org/2001/XMLSchema#string

Morgan GJ

http://www.w3.org/2001/XMLSchema#string

Muller GW

http://www.w3.org/2001/XMLSchema#string

Podar K

http://www.w3.org/2001/XMLSchema#string

P304

210-216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD.V98.1.210

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11418482

http://www.w3.org/2001/XMLSchema#string

P921